title: In reply.
authors.affiliation: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Auchus
authors.affiliation: Janssen Research & Development, Los Angeles, California, USA.
authors.forename: Margaret K
authors.initials: MK
authors.lastname: Yu
authors.affiliation: Janssen Scientific Affairs LLC, Johnson & Johnson, Horsham, Pennsylvania, USA.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Nguyen
authors.affiliation: Janssen Scientific Affairs LLC, Johnson & Johnson, Horsham, Pennsylvania, USA; Department of Biochemistry, Rush University Medical Center, Chicago, Illinois, USA.
authors.forename: Suneel D
authors.initials: SD
authors.lastname: Mundle
mesh_terms: D000736:Androstenes / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
chemical_list: D000736:Androstenes; D018931:Antineoplastic Agents, Hormonal; D011241:Prednisone